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Abstract: Methadone is used for the treatment of opioid addiction and for treatment of chronic
pain. The safety of methadone has been called into question by data indicating a large increase in
the number of methadone-associated overdose deaths in recent years that has occurred in parallel
with a dramatic rise in the use of methadone for chronic pain. The American Pain Society and the Col-
lege on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society, commis-
sioned an interdisciplinary expert panel to develop a clinical practice guideline on safer prescribing
of methadone for treatment of opioid addiction and chronic pain. As part of the guideline develop-
ment process, the American Pain Society commissioned a systematic review of various aspects related
Clinical practice guidelines are ‘‘guides’’ only andmay not apply to all pa-
tients and all clinical situations. As part of a shared decision-making
approach, it may be appropriate for the clinician to inform a patient
that a particular recommendation may not be applicable, after consid-
ering all circumstances pertinent to that individual.
This article is based on research conducted at the Oregon Evidence-based
Practice Center (now the Pacific Northwest Evidence-based Practice Cen-
ter) with funding from the American Pain Society (APS). The authors have
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solely responsible for the content of this article and the decision to
submit for publication.
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to safety of methadone. After a review of the available evidence, the expert panel concluded that
measures can be taken to promote safer use of methadone. Specific recommendations include the
need to educate and counsel patients on methadone safety, use of electrocardiography to identify
persons at greater risk for methadone-associated arrhythmia, use of alternative opioids in patients
at high risk of complications related to corrected electrocardiographic QTc interval prolongation, care-
ful dose initiation and titration of methadone, and diligent monitoring and follow-up. Although
these guidelines are based on a systematic review, the panel identified numerous research gaps,
most recommendations were based on low-quality evidence, and no recommendations were based
on high-quality evidence.
Perspective: This guideline, based on a systematic review of the evidence on methadone safety,
provides recommendations developed by a multidisciplinary expert panel. Safe use of methadone re-
quires clinical skills and knowledge in use of methadone to mitigate potential risks, including serious
risks related to risk of overdose and cardiac arrhythmias.
ª 2014 by the American Pain Society
Key words: Clinical practice guideline, methadone, safety, chronic pain, opioid addiction.
M
ethadone is a synthetic opioid used for the
treatment of opioid addiction and for treat-
ment of chronic pain.15,61 The safety of
methadone has been called into question by data
indicating a large increase in the number of
methadone-associated overdose deaths.38 This increase
appears largely related to the dramatic rise in the use
of methadone for chronic pain, though a small propor-
tion of deaths occur in patients treated for opioid addic-
tion.21,37,68,76,91,103 Methadone poisoning deaths in the
United States increased steadily from about 800 in 1999
to a high of about 5,500 in 2007; there was a decrease
to about 4,900 in 2008.101 The rate of increase in mortal-
ity has been substantially larger than for any other
opioid.32 About 1 of every 3 opioid-related deaths is
associated with methadone ingestion, a substantially
higher proportion than any other opioid.11 Although
this guideline focuses on methadone, clinicians should
also be aware of the overall rise in morbidity andmortal-
ity due to other prescription opioids.
The interpretation of data on methadone-associated
deaths is complicated by a number of factors, including
increased surveillance, differentiating prescribed versus
nonprescribed use ofmethadone, effects of other poten-
tial contributing factors (such as use of othermedications
and substances), and uncertainty regarding the degree
to which increases in deaths are proportionate to
increased prescribing. Ascribing cause of methadone-
associated death is a particular challenge. In the vast ma-
jority of cases, it is not possible to determinewhether the
death occurred as a result of respiratory depression
related to overdose or to other factors, such as
arrhythmia. Nonetheless, it is widely acknowledged
that the pharmacology of methadone may be associated
with unique safety concerns. This pharmacology includes
a long and variable half-life, potential interactions with
multiple medications, variability in equianalgesic dose
ratios depending on dose, and association with prolon-
gation of the corrected electrocardiographic QT (QTc) in-
terval, which may predispose patients to the ventricular
arrhythmia torsades de pointes.5,45,58,66,67,69,85,89 Data
from the Food and Drug Administration’s (FDA’s)
Adverse Event Reporting System indicate that since
2000, methadone was the second most commonly
suspected primary cause of drug-related arrhythmia, af-
ter dofetilide.51 The proportion of methadone-
associated deaths related to arrhythmia is likely to be
small relative to the proportion related to accidental
overdose, though reliable estimates are not available.
Three previous guidelines published between 2008 and
2011 addressed methadone safety, each focusing on pre-
vention of cardiac arrhythmias due to the association be-
tween methadone and prolonged QTc interval seen on
electrocardiogram (ECG).60,70,92 Two of these guidelines
were not fully endorsed by a professional society or
government entity60,92; the third was endorsed by the
Substance Abuse and Mental Health Services
Administration.72 Although systematic literature reviews
were conducted for these guidelines, a limitation is that
none graded the strength of the recommendations or
the quality of the evidence supporting the recommenda-
tions. In addition, they did not address methadone safety
issues other than cardiac arrhythmias.
Dear Reader,
The development of guidelines is a complex and costly
enterprise. Funding is increasingly reliant on providing
impact and outcome data. The American Pain Society re-
quests your assistance in evaluating the impact of the
Methadone Safety Guideline. Please follow this link
(http://www.surveygizmo.com/s3/1548754/APS-Metha
done-Survey) to complete a brief questionnaire before
reading the guideline. The survey consists of 11
multiple-choice questions and should take no more
than a few minutes.
We also seek readers willing to take a follow-up sur-
vey (see instructions at the end of this survey). These
data will assist the APS in developing data on guideline
impact and thus assist us in securing and determining
allocation of funding in the future. We are offering a to-
ken incentive for your participation.
Thank you for your cooperation.
Clinical Practice Guidelines Committee
American Pain Society
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The American Pain Society (APS) and the College on
Problems of Drug Dependence (CPDD), in collaboration
with the Heart Rhythm Society (HRS), commissioned an
interdisciplinary panel todevelopa clinical practice guide-
line on safer prescribing of methadone for treatment of
opioidaddictionandchronicpain.Aspart of theguideline
development process, APS commissioned a systematic re-
view on various aspects related to safety of methadone.17
Methods
Panel Composition
The APS and CPDD convened a panel of 16 members
with expertise in pain, addiction medicine, cardiology,
primary care, nursing, palliative care, pharmacology,
adolescent medicine, obstetrics and gynecology, epide-
miology, and social work to review the evidence and
formulate recommendations on methadone safety (see
Appendix 1 for list of panel members). Two cochairs
(R.A.C. and D.A.F.) were selected by the APS and CPDD
to lead the panel, which also included the APS Director
of Clinical Guidelines Development (R.C.). The HRS was
invited to join the guideline development process after
cochair and initial panel selection had taken place, and
it appointed 2 members with expertise in arrhythmia
(M.C.H. and D.M.) to the panel.
Target Audience and Scope
The intent of the Guideline is to provide, where
possible, evidence-based recommendations for use of
methadone in persons of all ages (including pregnant
women) for treatment of chronic pain in primary care
or specialty settings or for treatment of opioid addiction
in licensed opioid treatment programs. The target audi-
ence is all clinicians who prescribe methadone. Metha-
done is not approved by the FDA for use in acute or
postoperative pain, and its off-label use for these indica-
tions is outside the scope of this guideline, as is illicit use.
Funding and Conflicts of Interest
Funding for the Guideline was provided by the APS.
The Guideline was approved by APS and CPDD, but the
content of the Guideline is the responsibility of the au-
thors and panel members. All panelists were required to
disclose conflicts of interest within the preceding 5 years
at all face-to-facemeetings andprior to submissionof the
Guideline for publication, and to recuse themselves from
votes if a conflict was present. Conflicts of interest of the
authors and panel members are listed in Appendix 1.
Evidence Review
This Guideline is informed by a systematic evidence re-
view that addressed a variety of topics related
to methadone safety conducted at the Oregon
Evidence-based Practice Center and commissioned by
APS and CPDD.17 With the Oregon Evidence-based Prac-
tice Center, the panel developed the key questions,
scope, and inclusion criteria used to guide the evidence
review. Literature searches were conducted in multiple
electronic databases from their start date through July
2012. An update search was performed in January 2014
for new studies on methadone-related overdose and
arrhythmia. Details about the methods used to conduct
the review, including complete search strategies, are
available in the full report.17 Investigators reviewed
3,746 abstracts from electronic databases, reference lists,
and suggestions from expert reviewers. Two systematic
reviews and 168 primary studies (not included in previ-
ously published systematic reviews) were included in
the evidence report.17
Grading of the Evidence and
Recommendations
The panel used methods adapted from the Grading of
Recommendations Assessment, Development, and Eval-
uation Working Group to rate the recommendations
included in this Guideline.40 Each recommendation
received a separate grade for the strength of the recom-
mendation (strong or weak) and for the quality of evi-
dence (high, moderate, or low) (Appendix 2). In
general, a strong recommendation is based on the
panel’s assessment that the potential benefits of
following the recommendation clearly outweigh poten-
tial harms and burdens, or that the potential harms
clearly outweigh potential benefits. Given the available
evidence, most clinicians and patients would choose to
follow a strong recommendation. A weak recommenda-
tion is based on the panel’s assessment that benefits of
following the recommendation outweigh potential
harms and burdens (or vice versa), but the balance of
benefits to harms or burdens is smaller or evidence is
weaker. Decisions to follow a weak recommendation
could vary depending on specific clinical circumstances
or patient preferences and values. For grading the qual-
ity of a body of evidence that supports a recommenda-
tion, we considered the type, number, size, and quality
of studies; strength of associations or effects; and consis-
tency of results among studies.41 The quality of evidence
indicates the level of certainty in the recommendation
and the likelihood that future research could change rec-
ommendations. A recommendation based on low-
quality evidence has a high probability of being affected
by new evidence, and a recommendation based on high-
quality evidence has a low probability. Strong recom-
mendations based on low-quality evidence indicate
that until better evidence becomes available, the panel
determined that the benefits of following the recom-
mended course of action clearly outweigh harms. In
some cases, recommendations based on low-quality
evidence are followed by ‘‘practice advice’’ with more
specific suggestions for implementing the recommenda-
tion in clinical practice, based on panel consensus.
Guideline Development Process
The Guideline panel met in person inMay 2010 and July
2011. At the first meeting, the panel developed the scope
and key questions used to guide the systematic evidence
review. At the secondmeeting, the panel reviewed the re-
sults of the evidence review and drafted initial potential
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recommendation statements. Following the second
meeting, additional draft recommendation statements
were proposed. The panelists then participated in amulti-
stageDelphiprocess, inwhicheachdraft recommendation
was ranked on clinical importance and usefulness, and
revised. At each stage of the Delphi process, the lowest-
ranked recommendations were eliminated. A two-thirds
majority was required for a recommendation to be
approved. However, unanimous or near-unanimous
consensus was achieved for all recommendations. After
finalization of the recommendations, the Guideline was
written by various panel members and drafts distributed
to the panel for feedback and revisions. More than 20
externalpeer reviewers frommultiple clinical andscientific
disciplines and professional societies were solicited for
additional comments. After another round of revisions
and panel approval, the Guideline was approved by the
APS Board of Directors on May 7, 2013, and by the CPDD
Board of Directors on November 5, 2013.
The APS intends to update its clinical practice guide-
lines regularly. This Guideline and the evidence report
used to develop it will be reviewed and updated by
2018, or earlier if critical newevidencebecomes available.
The panel formulated the recommendations to be
generally applicable across age groups, though the great
bulk of evidence was in adult populations. Recommen-
dations were also developed to be applicable to metha-
done prescribing for treatment of both opioid addiction
and chronic pain, unless otherwise noted.
Recommendations
Patient Assessment and Selection
 When considering initiation of methadone, the panel
recommends that clinicians perform an individualized
medical and behavioral risk evaluation to assess risks
and benefits of methadone, given methadone’s spe-
cific pharmacologic properties and adverse effect pro-
file (strong recommendation, low-quality evidence).
Proper patient selection is critical when considering
the use of any opioid,whether for chronic pain or treat-
ment of addiction.16 This requires a comprehensive
benefit-to-harm evaluation based on a thorough his-
tory, review of records, and physical examination.
Opioid therapy generally is considered the mainstay
in the treatment of chronic moderate or severe pain
associated with active cancer or at end of life. In
contrast, for other types of chronic noncancer pain,
opioids are usually considered after other reasonable
pain management strategies have proved ineffective.
In all populations, opioids should be considered only
in the context of information that weighs the potential
beneficial effects of prescribed opioids against risks,
including those related to their potential for abuse,
addiction, diversion, overdose, relapse (for patients
treated for addiction), and other adverse events. The
assessment should include evaluation of biomedical,
psychosocial, and cultural issues that may affect use
of and adherence to methadone treatment. An Amer-
ican Pain Society–American Academy of Pain Medicine
(APS-AAPM) Guideline provides additional details on
patient assessment and selection when opioid therapy
is under consideration for chronic pain.16 This Guide-
line recommends that clinical findings or the results
of specific assessment tools be used to stratify patients
according to the assessed risk of substance abuse out-
comes, and that this assessment be used in deciding
whether to proceed with a trial of an opioid.
Once a decision is made to undertake a trial of
long-term opioid therapy for pain, or to continue
treatment that has provided benefit, a second analysis
is needed to determine whether methadone may be
an appropriate analgesic. This assessment is informed
by many factors, as described below. When metha-
done is considered for the treatment of opioid addic-
tion, other factors are considered, such as the level of
physical dependence, presence of a structured envi-
ronment, involvement in ongoing treatment and re-
covery activities, patient stability, prior experience
with addiction treatments, concurrently prescribed
medications, other drug abuse, current comorbidities,
and patient preferences for opioid therapy. When
treating patients with chronic pain, given the avail-
ability of alternatives, clinicians should always consider
whether another opioid may be a more appropriate
therapy, when an opioid is indicated.
The necessity for additional evaluation concerning
the specific use of methadone for pain and addiction
is based on unique pharmacologic properties that
can affect determinations of benefits relative to risks,
which include a long and variable half-life, numerous
drug-drug interactions (including alcohol), and effects
on the electrocardiographic QTc interval and respira-
tory depression. For example, a patient otherwise as-
sessed as an appropriate potential candidate for
opioid treatment who is taking a medication with po-
tential methadone interactions or has risk factors for
QTc interval prolongation or known QTc interval pro-
longation may be more appropriately treated with
an alternative opioid (see below).45,58,67,69
Patient Education and Counseling
 The panel recommends that clinicians educate and
counsel patients prior to the first prescription of meth-
adone about the indications for treatment and goals
of therapy, availability of alternative therapies, and
specific plans for monitoring therapy, adjusting doses,
potential adverse effects associated with methadone,
andmethods for reducing the risk of potential adverse
effects and managing them (strong recommendation,
low-quality evidence).
As with any other opioid, clinicians should counsel
patients about potential risks and benefits before initi-
ating a trial of methadone. During treatment, clini-
cians should periodically review risks and benefits of
therapy. An APS-AAPM guideline on opioid therapy
for chronic pain provides additional details regarding
suggested elements of patient education in the setting
of pain management, as well as a sample informed
consent form.16
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In addition to common opioid-related adverse
events, clinicians should discuss specific risks associated
with methadone and factors that may be associated
with overdose.32,38 These include methadone’s long
and variable half-life, the potential association be-
tween use ofmethadone andQTc interval prolongation
and cardiac arrhythmia, and the potential for drug-
drug interactions.45,58,67,69 Patients should be
specifically informed about methods for mitigating
risks, including the importance of taking methadone
as prescribed and adherence with recommended
follow-up and monitoring. Patients seen in clinical set-
tings other than the one in which methadone is pre-
scribed should be informed that their receipt of
methadone will not be apparent if it is not linked to
the electronic medical records of that setting or to state
prescription-monitoring programs, and they should be
educated about the importance of disclosing its use. Pa-
tients, aswell as caregivers and familymemberswhoare
actively engaged in the patient’s care, should be noti-
fied about the risks of respiratory depression and in-
structed to withhold additional doses of methadone
and contact the prescribing or dispensing entity if signs
of respiratory depression or somnolence are present.
Patients should be instructed tonever sharemethadone
and to storemethadone in a safe place, such as a locked
cabinet or box if necessary, to safeguard against theft.
An opioid management plan describes how metha-
donewill be prescribed andmonitored in an individual
patient. It is distinct from the informed consent pro-
cess, which refers to a discussion of the potential
benefit and harms of a therapy. As for all opioids, the
management plan when prescribing methadone for
treatment of chronic pain may include elements in-
tended to help monitor and verify use. These may
include the stipulation that methadone is obtained
from one prescriber or facility, prescriptions are filled
at one designated pharmacy, drug screening is per-
formed periodically, office visits are required at a spec-
ified minimum interval, pill counts are conducted at
office visits, and prescription size is limited (eg, weekly
or biweekly instead of monthly amounts in higher-risk
patients).16 To ensure that key messages are conveyed
to patients consistently, prescribers should consider
the use of a written methadone management plan.16
This plan may also include enumeration of behaviors
that may result in discontinuation of methadone.
Baseline Electrocardiograms
 The panel recommends that clinicians obtain an ECG
prior to initiation of methadone in patients with risk
factors for QTc interval prolongation, any prior ECG
demonstrating a QTc >450 ms, or a history suggestive
of prior ventricular arrhythmia. An ECG within the
past 3 months with a QTc <450 ms in patients without
new risk factors for QTc interval prolongation can be
used for the baseline study (strong recommendation,
low-quality evidence).
 The panel recommends that clinicians consider obtain-
ing an ECG prior to initiation of methadone in patients
not known to be at higher risk for QTc interval prolon-
gation; an ECG within the past year with a QTc <450 ms
in patientswithout new risk factors forQTc interval pro-
longation can be used for the baseline study (weak
recommendation, low-quality evidence).
Torsades de pointes is a polymorphic ventricular
arrhythmia usually preceded by QTc interval prolonga-
tion22,96 that can lead to ventricular fibrillation and
result in sudden death or cardiac arrest.22,84 The risk
of torsades de pointes increases with greater
prolongation of the QTc interval. Torsades de pointes
primarily occurs in patients with QTc intervals
>500 ms, though risk is increased starting around QTc
intervals of 450 ms.22,74,80,88 Although normal QTc
intervals are longer in women than in men, with an
average difference of 10 to 20 ms, it is unclear
whether there are sex differences in risk of torsades
de pointes at increased QTc intervals. Therefore, for
pragmatic purposes, the panel recommends that
clinicians utilize the same QTc interval parameters for
men and women. Risk factors for QTc interval
prolongation include22,26,31,47,93,96
 electrolyte abnormalities such as hypokalemia or hy-
pomagnesemia;
 impaired liver function;
 structural heart disease (such as congenital heart de-
fects or a history of endocarditis or heart failure);
 genetic predisposition such as congenital prolonged
QTsyndrome or familial history of prolongedQTsyn-
drome; and
 use of drugs with QTc-prolonging properties
(Table 1).
Methadone use appears to be associated with risk
of prolongation of the QTc interval,26,55,59,66,69,89
presumably because of its potent inhibitory effects on
the human ether a go-go-related gene (hERG) cardiac
channel,52,95 and case reports describe torsades de
pointes in patients prescribed methadone.47,57,77 Other
medications associated with QTc interval prolongation
and torsades de pointes include various
antiarrhythmics, antipsychotics, citalopram, tricyclic
antidepressants, fluoroquinolones, and cisapride.106
The estimated risk of torsades de pointes varies widely,
ranging from approximately .001% for cisapride to
approximately 8% for quinidine.22 In the case of cisapr-
ide, the manufacturer discontinued marketing of the
drug in the United States in 2000, based on 341 cases of
cardiac arrhythmias (including 80 deaths) between
1993 and 1999.98 Although estimates for the degree of
risk associatedwithdrug-inducedQTc interval prolonga-
tion vary, in patientswith longQTsyndrome, aQTc inter-
val >500 ms was associated with an odds ratio for
syncope or sudden death (presumably due to torsades
de pointes) of 4.2 (95% confidence interval [CI] 1.1–
16).8 Becauseofpotential cardiac arrhythmia risk, abase-
line ECG is recommended prior to initiating a number of
these medications, with periodic ECG monitoring of pa-
tients taking themedications, though evidence showing
the effectiveness of ECG monitoring is lacking.1-3,18,22,23
Similarly, in patients being considered for metha-
done, a baseline ECG may help clinicians assess for
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risk of torsades de pointes, based on the presence and
degree of QTc interval prolongation prior to medica-
tion initiation. Accurate estimates on the risk of tor-
sades de pointes or sudden cardiac death are not
available. Recent data suggest that methadone is the
most common drug-related cause of ventricular ar-
rhythmias reported to the FDA.4,51 However, some
studies suggest that in patients on methadone for
opioid addiction, attributable mortality appears
low.4 Although no study has evaluated the effect of
ECG screening and monitoring on clinical outcomes,
and the clinical opinion on the need to obtain ECGs
in patients being considered for methadone varies
markedly, in part because of concerns about delayed
or reduced access to methadone, an ECG is the only
way to detect asymptomatic QTc interval prolonga-
tion. Patients with QTc interval prolongation might
benefit from efforts to address causes of QTc interval
prolongation, consideration of alternative opioids or
other interventions, or additional monitoring if pre-
scribed methadone. Although no study has compared
outcomes associated with different ECG strategies in
this setting, the panel recommends that clinicians
routinely obtain an ECG prior to initiation of metha-
done in patients with known risk factors for QTc inter-
val prolongation, a prior ECG with QTc interval
>450 ms, or a history suggestive of prior ventricular
arrhythmia (such as prior cardiac arrest and unex-
plained syncope or seizure). Approximately 85% of
cases of cisapride-associated cardiac arrhythmias
occurred in patients with known risk factors for QTc in-
terval prolongation.98 Although data are limited,
studies of methadone-associated torsades de pointes
similarly indicate that a high proportion of patients
had identifiable risk factors.47,58,77,99
For persons not known to be at a higher risk of QTc
interval prolongation, the panel found insufficient ev-
idence to routinely recommend ECG screening.
Table 1. Selected Methadone Drug-Drug
Interactions
DRUG
EFFECTS ON
METHADONE
LEVELS*
EFFECTS ON
QTC INTERVAL
ADDITIVE
SEDATIVE OR
RESPIRATORY
DEPRESSANT EFFECTS
Antibiotics
Ciprofloxacin [
Clarithromycin [ [
Erythromycin [ [
Itraconazole [
Ketoconazole [
Fluconazole [
Rifampin Y
Telithromycin [
Anticonvulsants
Carbamazepine Y
Phenytoin Y
Antihistamines
Diphenhydramine [
Promethazine [
Antipsychotics
Quetiapine [ [
Barbiturates
Phenobarbital Y [
Benzodiazepines
Alprazolam [ [
Clorazepate [ [
Diazepam [ [
Estazolam [ [
Flurazepam [ [
Lorazepam [ [
Midazolam [ [
Triazolam [ [
Zopiclone [ [
HIV medications
Abacavir Y
Nevirapine Y
Delavirdine [
Efavirenz Y
Ritonavir-boosted
lopinavir
Y
Nelfinavir Y
Amprenavir Y
Atazanavir Y
Opioids [
Heroin Y* [
Selective serotonin reuptake inhibitors
Fluoxetine [
Fluvoxamine [
Nefazodone [
Paroxetine [
Sertraline [
Tricyclic antidepressants
Amitriptyline [
Desipramine [
Imipramine [
Nortriptyline [
Protriptyline [
Urinary alkalinizers
Bicitra [
Polycitra [
Verapamil [
Other
Table 1. Continued
DRUG
EFFECTS ON
METHADONE
LEVELS*
EFFECTS ON
QTC INTERVAL
ADDITIVE
SEDATIVE OR
RESPIRATORY
DEPRESSANT EFFECTS
Aprepitant [
Cimetidine [
Cocaine Y [
Disulfiram [
Ethanol Y* [
Grapefruit juice or
whole fruit
[
Omeprazole [
St. John’s wort Y*
NOTE. Most effects are predicted or expected drug interactions; in most cases
direct evidence on changes in methadone levels on and off the second medica-
tion are not available. Cytochrome P450 inducers decrease methadone blood
levels; inhibitors increase methadone blood levels. More comprehensive and
periodically updated lists of cytochrome P450 interactions and drugs associated
with QTc prolongation are available at http://medicine.iupui.edu/clinpharm/ddis/
ClinicalTable.aspx and http://QTdrugs.org.
*Data not as strong for interaction.
Leavitt63; McCance-Katz et al,72 Lintzeris et al,65 and Gourevitch et al.40
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However, given that QTc interval prolongation
without arrhythmia is asymptomatic and may not be
associated with recognized risk factors, the panel sug-
gests that clinicians consider obtaining an ECG prior to
initiation of methadone in all patients.
Although there is noevidence toguide recommenda-
tions on how recent an ECG should be to guide risk as-
sessments accurately prior to initiation of methadone,
the panel suggests that in patients with risk factors for
QTc interval prolongation that are unchanged, an ECG
within the last 3 months showing no QTc interval pro-
longation canbeusedas thebaseline studyanda repeat
ECG is unnecessary prior to initiatingmethadone. In pa-
tientswith no risk factors forQTc interval prolongation,
anECGwithin the last year showingnoQTc intervalpro-
longation can be used as the baseline study.
Thepanel foundextremely limited evidence toguide
use of screening ECGs prior to initiation of methadone
in children. Although research on longQTsyndrome in
families indicates a two- to fourfold increased risk of
cardiac events in children with QTc intervals between
460 and 500 ms,109 the panel found no reported cases
of torsades de pointes in children prescribed metha-
done, despite relatively common pediatric use in
some hospital settings. Nonetheless, given the poten-
tial for increased cardiovascular risk, thepanel suggests
that clinicians consider a screening ECG prior to initi-
ating methadone in children with risk factors for pro-
longed QTc interval, as described above.
 The panel recommends against use of methadone in
patients with a baseline QTc interval >500 ms (strong
recommendation, low-quality evidence).
 The panel recommends that clinicians consider alternate
opioids in patients with a baseline QTc interval$450 ms
but<500ms. Ifmethadone is considered inapatientwith
abaselineQTc interval$450msbut<500ms, theclinician
should evaluate for and correct reversible causes of QTc
interval prolongation before initiating methadone
(weak recommendation, low-quality evidence).
 The panel recommends that clinicians consider bupre-
norphine as a treatment option for patients treated for
opioid addiction who have risk factors for or known
QTc interval prolongation when an agonist/partial
agonist is indicated (weak recommendation,
moderate-quality evidence).
A QTc interval of $500 ms is associated with a sub-
stantially increased risk of torsades de pointes.22,74,80,88
In adults, each 10-ms increase in QTc interval is
associated with an approximate 5 to 7% exponential
increase in risk of torsades, so that a patient with a
QTc of 540 ms has a 63 to 97% greater risk than a
patient with a QTc of 440 ms.22 Patients with this de-
gree of QTc interval prolongation prior to starting
methadone may experience further QTc interval pro-
longation on methadone, placing them at greater
risk.2-14,28,30,31 Therefore, the panel recommends
against use of methadone in adults with a QTc
interval $500 ms at baseline. In such patients, the
panel recommends that clinicians consider alternative
treatments for chronic pain or opioid addiction. For
patients being managed for chronic pain, a number
of alternative opioids are available. Although QTc
interval prolongation has been reported with
oxycodone, its clinical significance is uncertain.30 Other
opioids have not been associatedwithQTc interval pro-
longation in clinical studies. For the treatment of
opioid addiction, buprenorphine has similar efficacy
to moderate doses of methadone but is associated
with less QTc interval prolongation, and is one poten-
tial alternative.4,6,28,29,42,56,102 A QTc interval of 450 to
500 ms in adults is also associated with increased risk
of torsades de pointes.47,57,77 Data from general
populations of U.S. adults indicate that less than 5%
of men and women have QTc intervals of
>450 ms.83,111 Although the risk associated with a QTc
interval of 450 to 500 ms is lower than in patients
with QTc intervals of >500 ms, the panel recommends
that clinicians consider alternatives to methadone
because there may be some additional risk. Factors to
consider when deciding whether to initiate
methadone include the degree of QTc interval
prolongation (intervals close to 450 ms are associated
with less risk than intervals closer to 500 ms) and
whether there may be reversible risk factors. In
patients who are prescribed other medications that
prolong QTc interval or who have hypokalemia, the
panel recommends that clinicians stop the other
medications if clinically appropriate and correct
hypokalemia. In such cases, the decision to initiate
methadone would depend in part on whether the
QTc interval improved after such measures. In patients
with nonreversible risk factors such as structural heart
disease or cirrhosis, the use of alternatives to
methadone may be more strongly considered.
However, the efficacy of alternative treatments, as
well as the risks of inadequate or no treatment, must
be considered, especially in treatment of addiction.
Patients with a QTc interval <450 ms at baseline are
not considered to be at increased risk for torsades de
pointes following initiation of methadone, and may
be started on methadone with routine follow-up and
monitoring (see below).
The panel found insufficient evidence to determine
whether QTc thresholds for use of methadone should
differ in children compared with adults. As in adults,
data generally indicate that <5% of children have a
QTc interval >450 ms.44,79,97 In addition, as noted
above, studies of siblings of children with long QT
syndrome found increased risk of cardiovascular
events at QTc intervals of 460 to 500 ms, though
reported cases of torsades de pointes in children
prescribed methadone are rare. Given the potential
for increased risk and the availability of alternative
opioids, the panel suggests that clinicians apply
similar QTc parameters for use of methadone in
children as in adults, until more evidence is available.
Initiation of Methadone
 The panel recommends that clinicians initiate metha-
done at low doses individualized based on the
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indication for treatment and prior opioid exposure sta-
tus, titrate doses slowly, andmonitor patients for seda-
tion (strong recommendation, moderate-quality
evidence).
Practice Advice: Based on limited research evidence
and clinical experience, the panel suggests the following
parameters:
1) When used to treat opioid addiction, the panel sug-
gests that clinicians start methadone at no more
than 30 to 40 mg once daily. The dose should be
titrated based on objective signs of withdrawal
and self-reported craving and methadone dose
increased by no more than 10 mg/d and no more
frequently than every 3 to 4 days. Methadone
should be withheld if there is evidence of sedation.
2) When used to treat chronic pain in adults on rela-
tively low doses of other opioids (eg, <40–60 mg/
d of morphine or equivalent), the panel suggests
that clinicians start methadone at 2.5 mg tid, with
initial dose increases of no more than 5 mg/d every
5 to 7 days. In children, the recommended starting
dose is 100 mg/kg (maximum 5 mg/dose) every 6 to
8 hours. Methadone should be withheld if there is
evidence of sedation.
3) When used to treat chronic pain and switching to
methadone from higher doses of another opioid,
the panel suggests that clinicians start methadone
therapy at a dose 75 to 90% less than the calcu-
lated equianalgesic dose and at no higher than
30 to 40 mg/d, with initial dose increases of no
more than 10 mg/d every 5 to 7 days. Methadone
should be withheld if there is evidence of
sedation.
 The panel recommends that clinicians consider those
patients previously prescribed methadone, but
who have not currently taken opioids for 1 to 2 weeks,
opioid-na€ıve for the purpose of methadone reinitia-
tion (strong recommendation, low-quality evidence).
The panel recommends that clinicians start metha-
done at low doses and titrate slowly. Evidence to guide
optimalmethadone initiation and dose titration strate-
gies is limited. Therefore, suggestions for practice
are based on panel consensus and clinical experience,
and depend on the degree to which a patient is
opioid-experienced, with an overarching goal of
more conservative (lower) initial dosing regimens in or-
der to prioritize patient safety. The rationale for the
panel’s recommendation for careful initiation and
dose titration of methadone is related to the drug’s
long and highly variable half-life.67 Slow titration
may reduce the risk of unintended accumulation that
can occur as the serum concentration slowly rises to-
ward steady state once a dose is selected. It is possible
that rapid titration of the dose to a level that is effica-
cious for pain could be followed by toxicity over the
course of the next days or evenweeks as the concentra-
tion rises. In themost serious outcome, this late toxicity
could take the form of respiratory depression and
death. Consistent with this principle is evidence
showing that the period shortly following methadone
initiation appears to be associated with increased risk
of overdose and other adverse events.27,37,108
Although the half-life ofmethadone is usually assumed
to be approximately 1 day, and is rarely outside a range
of 15 to 60 hours, in some reports the half-life is as high
as 120 hours.67 By comparison, the plasma half-life of
morphine, hydromorphone, oxycodone, fentanyl, and
codeine range from 2 to 3.5 hours.45 In a patient for
whom the methadone half-life is 60 hours, it would
take almost 12 days on a stable dose of methadone to
approach a steady state (5 half-lives). In addition, pa-
tients with a long half-life will have more prolonged
exposure to a given methadone dose, potentially
increasing their risk for adverse events. Without
knowing the half-life in an individual patient, risk can
be minimized only by cautious titration. Clinicians
should be aware that the variable half-life of metha-
done means that some patients may not reach steady
state (5 half-lives) for over 3 weeks. Therefore, it is crit-
ical that clinicians not increase the dose solely based on
preset parameters, but also evaluate patients clinically
and withhold the dose if there is evidence of sedation.
Once the sedation has resolved, methadonemay be re-
initiated at a lower dose (eg, at least 20% lower than
the dose that caused sedation) and the period between
dose titrations extended.
The panel recommends particular caution when
initiating methadone for pain treatment in patients
with no prior exposure to opioids (‘‘opioid-na€ıve’’). In
this situation, the panel suggests a starting dose of
2.5 mg every 8 hours (7.5 mg/d), with initial dose in-
creases of no more than 5 mg/d every 5 to 7 days, in
accordance with the APS-AAPM Guideline.16 Once
the dose has reached 30 to 40 mg/d and the patient
has shown the ability to tolerate dose increases of
5 mg/d, clinicians may consider larger dose increases
of up to 10 mg/d, though the duration between dose
increases should not be shortened. Evidence indicates
that the risk of overdose is increased at higher doses
of opioids, suggesting that dose increases of metha-
done above 30 to 40 mg/d should only be done in pa-
tientswho are clearly benefiting and can bemonitored
appropriately.7,24,39
In children, the panel suggests a starting dose of 100
mg/kg (maximum5mg/dose initially) every 6 to 8 hours.
Although the World Health Organization suggests a
higher potential starting dose (100–200 mg/kg) with
several initial loading doses (2–3 doses given every
4 hours),105 the panel felt that more cautious initiation
of methadone is warranted in children with chronic
pain, particularly in nonhospital settings. The panel
suggests use of short-acting opioids for breakthrough
pain or if more rapid initial pain control is needed,
rather than loading doses of methadone. As in adults,
the panel recommends dose increases in children no
more frequently than once every 5 to 7 days, based
on the amount of breakthrough pain medications
needed to maintain pain control, by no more than
50% of the current methadone dose.
For patients treated for opioid addiction and
engaged in ongoing opioid use, higher starting doses
and more rapid dose titration may decrease the
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likelihood of withdrawal and increase the likelihood
of treatment success. In such patients, clinicians may
consider starting at higher doses than used in
opioid-na€ıve patients. The panel suggests initiating
methadone at up to 30 to 40 mg once daily and
titrating the dose based on objective signs of with-
drawal and self-report of opioid craving, but by no
more than 10 mg/d and with dose increases no
more frequently than every 3 to 4 days.
In patients with chronic pain on higher doses of
alternative opioids, conversion to methadone should
be performed carefully. Proposed equianalgesic dose
ratios for conversion of other opioids (in mg
morphine equivalents) to methadone are variable
and range from 3:1 to 10:1 at lower doses to 8:1 to
20:1 at higher doses.78 In patients on lower doses of
other opioids (eg, <40–60 mg morphine equivalents/
d), the panel suggests starting methadone at doses
similar to those recommended for opioid-na€ıve pa-
tients. For patients on higher doses of other opioids,
the panel suggests that clinicians start methadone
at a dose 75 to 90% less than the calculated equianal-
gesic dose, based on more conservative dosing ratios
(eg, 15:1 to 20:1) and at no higher than 30 to 40 mg/
d.14 Initial dose increases should be no more than
10 mg/d every 5 to 7 days.
The panel recommends that clinicians reinitiate
methadone cautiously in patients who have previously
been prescribed methadone but are currently not tak-
ing an opioid. Such patients experience loss of toler-
ance and are at risk for accidental overdose if
reinitiated at their previously tolerated methadone
dose. Although there is insufficient evidence to deter-
mine with precision how quickly tolerance is lost, the
panel suggests that clinicians treat patients not taking
opioids for 1 to 2 weeks as opioid-na€ıve.
Because of its long half-life and variable pharmaco-
kinetics, the panel recommends that methadone not
be used to treat breakthrough pain or as an as-
needed medication.16
Follow-Up Electrocardiograms
 The panel recommends that for patients prescribed
methadone, clinicians perform follow-up ECGs based
on baseline ECG findings, methadone dose changes,
and other risk factors for QTc interval prolongation
(strong recommendation, low-quality evidence).
Practice Advice: Based on limited research evidence
and based upon clinical experience, the panel suggests
the following parameters:
1) The panel suggests that for patients with risk fac-
tors for QTc interval prolongation, any prior ECG
demonstrating a QTc >450 ms, or a history of syn-
cope, clinicians perform follow-up ECG 2 to 4weeks
after initiation of methadone therapy and
following significant dose increases.
2) The panel suggests that for all patients, clinicians
perform follow-up ECG when the methadone
dose reaches 30 to 40 mg/d in patients started at
lower doses, and again at 100 mg/d.
3) The panel suggests that clinicians perform follow-
up ECG for all patients prescribed methadone
with new risk factors for QTc interval prolongation
or signs or symptoms suggesting arrhythmia.
 The panel recommends that clinicians switch
methadone-treated adults with a QTc interval
$500 ms to an alternative opioid or immediately
reduce themethadone dose; in all such cases, the panel
recommends that clinicians evaluateandcorrect revers-
ible causes ofQTc interval prolongation, and repeat the
ECG after the methadone dose has been decreased
(strong recommendation, low-quality evidence).
 The panel recommends that clinicians consider switch-
ing methadone-treated adults with a QTc interval
$450 ms but <500 ms to an alternative opioid or
reducing the methadone dose. In patients in whom
there are barriers to switching to alternative opioids,
or who experience decreased treatment effectiveness
with methadone dose reductions, the panel recom-
mends that clinicians discusswith patients the potential
risksof continuedmethadone. Inall cases, thepanel rec-
ommends that clinicians evaluate and correct reversible
causes ofQTc interval prolongation, and repeat theECG
after the methadone dose has been decreased (strong
recommendation, low-quality evidence).
Follow-up ECGs in patients prescribed methadone
may be useful for identifying QTc interval prolonga-
tion that increases the risk for torsades de pointes.
Although there is no evidence to guide optimal stra-
tegies for performing follow-up ECGs, the panel sug-
gests that clinicians obtain a follow-up ECG soon
after initiating methadone in patients with QTc in-
terval prolongation at baseline and in patients on
methadone with new risk factors for QTc interval
prolongation of signs or symptoms suggesting ven-
tricular arrhythmia (such as palpitations, presyncope,
or syncope). In addition, some evidence suggests that
the degree of QTc interval prolongation is dose
dependent.13,26,29,53,57,69 Therefore, follow-up ECGs
should also be obtained when methadone daily
doses are increased to certain threshold levels.
Although there are insufficient data to determine
optimal methadone dose threshold levels for ECG
monitoring, the panel suggests 30 to 40 mg/d in pa-
tients started at lower doses, and again at 100 mg/d.
The panel suggests that clinicians obtain a follow-up
ECG 2 to 4 weeks after initiation of methadone in pa-
tients with a QTc interval >450 ms at baseline, a history
of syncope prior to initiation of methadone, or risk fac-
tors for QTc interval prolongation, as well as when pa-
tients develop new risk factors for QTc interval
prolongation or report signs or symptoms suggesting
potential arrhythmia. In patients started on low doses
of methadone, the panel also recommends that clini-
cians perform follow-up ECG when the methadone
dose reaches the thresholds notedpreviously. Thepanel
found insufficient evidence to suggest parameters for
follow-up ECGs in patients titrated to higher metha-
done doses who do not experience QTc interval prolon-
gation at doses of 100 mg/d or lower. However, a high
proportion of case reports of torsades de pointes in
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patients prescribed methadone occurred at high doses
(>200 mg/d), suggesting that additional monitoring at
higher doses (eg, whenever the dose is titrated to 30–
50%higher than theprior doseatwhichanECGwasob-
tained) may be warranted.47,57 In patients with QTc
interval prolongation on follow-up ECG, recommenda-
tions on use of methadone, consideration of alterna-
tives, and correction of potentially reversible causes
are similar to thosedescribedabove forQTc intervalpro-
longation on a baseline ECG. In addition, cliniciansmay
consider lowering the methadone dose with follow-up
to document improvement or normalization of the
QTc interval.28,42,59 For patients treated for opioid
addiction who develop a prolonged QTc interval on
methadone, buprenorphine is a potential alternative.
Buprenorphine has similar efficacy to moderate
doses of methadone for treatment of opioid
addiction, and observational studies report
normalization of prolonged QTc intervals after
switching patients from methadone to
buprenorphine.28,42,59 For chronic pain, a number of
opioids are available as alternatives to methadone. A
potential limitation to use of buprenorphine is that it
is a m-opioid partial agonist and may exhibit analgesic
ceiling dose effects at which further dose increases pro-
duce no additional effects.100 Clinicians switching pa-
tients from methadone to buprenorphine should also
follow recommended methods to avoid precipitated
withdrawal due to initiation of a partial agonist.10
Monitoring for and Management of
Adverse Events
 The panel recommends that patients receiving metha-
done bemonitored for common opioid adverse effects
and toxicities and that adverse effects management be
considered part of routine therapy (strong recommen-
dation, moderate-quality evidence).
In addition to QTc interval prolongation, metha-
done is associated with other adverse effects typically
associated with opioids, including constipation,
nausea, sedation, respiratory depression, pruritus,
endocrinologic effects, and others. As outlined in the
APS-AAPM guideline on use of opioids for chronic
noncancer pain, the panel recommends that clinicians
anticipate and routinely monitor patients prescribed
methadone for opioid-related adverse effects.16
Adverse effects management, including proactive in-
terventions, should be considered part of routine ther-
apy in all patients prescribed methadone. Clinicians
should routinely consider initiation of a bowel
regimen to prevent or manage opioid-induced consti-
pation. Although evidence is anecdotal, regimens
including increased fluid and fiber intake, stool soft-
eners, and laxatives are often effective. For nausea
and vomiting, a number of antiemetics, in both oral
and rectal forms, are available, though some are asso-
ciated with QTc interval prolongation (see below).
Patients should be asked about signs or symptoms of
hypogonadism and appropriately tested when pre-
sent. Clinicians should recognize comorbidities that
may increase the risk of opioid-related adverse effects
such as sleep apnea or other underlying respiratory dis-
ease, dementia, or antecedent constipation. Close
monitoring is recommended in such cases.
Clinicians should periodically monitor patients for
the development of substance abuse and other mental
health disorders. Such patients should be managed
appropriately, including referral if necessary and po-
tential discontinuation or restructuring of methadone
therapy. Clinicians should also periodically review state
prescription drugmonitoring program data, which are
nowwidely available, in order to help identify patients
who are obtaining opioids or other controlled sub-
stances from other providers, as such behaviors are
associated with increased risk of overdose.
Patients should be counseled on sedation after
opioid initiation andwith dose increases, including po-
tential issues related to driving and work and home
safety. However, most epidemiologic studies suggest
that risk of motor vehicle accidents, traffic fatalities,
and citations for impaired driving is not increased in
patients on stable doses of opioids.34,35 In the
absence of signs of symptoms of impairment, the
panel did not identify sufficient evidence to support
restrictions in driving or most work-related activities
in patients maintained on long-term opioid therapy.16
 The panel recommends face-to-face or phone assess-
ment with patients to assess for adverse events within
3 to 5 days after initiating methadone, and within 3 to
5 days after each dose increase (strong recommenda-
tion, low-quality evidence).
The risk of methadone-associated mortality is higher
shortly after initiating methadone.9,61,73,107 Although
evidence is sparse on the association between
methadone dose increases and serious adverse events,
a similar association appears plausible. Therefore, the
panel recommends that clinicians reassess patients 3 to
5 days following methadone initiation or after
methadone dose increases, with particular attention
to signs of respiratory depression (such as decreased
respiratory rate or sedation, which may accompany
respiratory depression) and arrhythmia (such as
palpitations). Although there is insufficient evidence
to guide recommendations on optimal methods or
timing for follow-up, the panel recognizes that
follow-up assessments do not necessarily require an of-
fice visitwithaprovider, andmaybeperformedover the
phone by an appropriately trained medical assistant or
nurse or via email for reliable patients.
Urine Drug Testing
 The panel recommends that clinicians obtain urine
drug screens prior to initiating methadone and at reg-
ular intervals in patients prescribed methadone for
opioid addiction (strong recommendation, low-
quality evidence).
 The panel recommends that patients prescribed meth-
adone for chronic pain who have risk factors for drug
abuse undergo urine drug testing prior to initiating
methadone and at regular intervals thereafter; it
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recommends that clinicians consider urine drug testing
in all patients regardless of assessed risk status (strong
recommendation, low-quality evidence).
One method to monitor patients prescribed opioids
is urine drug testing (UDT). UDT may help identify pa-
tients engaging in aberrant drug-related behaviors
and who may benefit from restructuring of their
opioid therapy or treatment of underlying addiction
or opioid misuse. Although no study has evaluated
optimal UDT intervals in patients prescribed metha-
done or other opioids, the panel suggests that clini-
cians obtain a baseline UDT, including specific testing
for methadone, in all patients prescribed methadone
for opioid addiction and in all patients prescribed
methadone for chronic pain that have risk factors for
drug abuse. Subsequent UDT should be performed
periodically if justified based on the patients’ assessed
risk for drug abuse or diversion. The APS-AAPM guide-
line on use of opioids for chronic noncancer pain sug-
gests that clinicians use the risk assessment to help
guide UDT monitoring intervals.16 Patients treated
for opioid addiction are at high risk for opioid abuse
and misuse and generally warrant frequent moni-
toring. Patients prescribed methadone for chronic
pain who may need more frequent or intense moni-
toring include those with a prior history of substance
use disorder, patients with an unstable or dysfunc-
tional social environment, and those with comorbid
psychiatric conditions. In patients treated for chronic
pain at low risk for adverse outcomes and on stable
doses of opioids, the APS-AAPM guideline also sug-
gests that clinicians consider UDT monitoring, as evi-
dence indicates that a substantial minority of
patients who engage in aberrant drug-related behav-
iors do not have identifiable risk factors.48,54 In such
patients, repeat testing every 6 to 12 months may be
sufficient, though clinic follow-up every 3 to 6 months
is generally suggested.
Medication Interactions
 The panel recommends that clinicians use methadone
with care in patients using concomitant medications
withpotentially additive sideeffectsorpharmacokinetic
or pharmacodynamic interactions with methadone
(strong recommendation, low-quality evidence).
Evidence on the magnitude of clinical harms associ-
ated with the concomitant use of methadone plus po-
tential interacting medications is limited, and most
trials were not designed to evaluate serious harms.
However, several types of drug interactions can in-
crease risk in patients using methadone and therefore
require attention and care in prescribing (Table 1).
These include use of drugs that
 alter methadone absorption, metabolism, and/or
excretion, thereby changing methadone blood
levels;
 have additive or synergistic sedative or respiratory
suppressant effects; and/or
 prolong QTc intervals.
Like other opioids, methadone is primarily
metabolized in the liver and gastrointestinal tract25 by
cytochrome P450 (CYP) enzymes including CYP2B6,
CYP3A4, CYP 2C19, CYD2D6, and CYP1A2.62,104 Many
other medications can affect the metabolism of
methadone and other opioids because they are CYP
inhibitors (leading to increased opioid levels)63 or
CYP inducers (leading to decreased opioid levels).36
CYP inhibitors may increase risk for sedation and respi-
ratory depression at a specific opioid dose, and CYP in-
ducers may reduce effectiveness of methadone at a
specific dose or precipitate withdrawal.
In addition, like other opioids, methadone has
sedating and respiratory depressant effects that may
be augmented by use of medications and drugs (such
as alcohol) with similar effects. In particular, a high pro-
portion of cases of overdoses involving methadone
occurred in patients with benzodiazepines in their sys-
tem at the time of death.12,37,90,94,103 The panel
suggests that clinicians generally avoid
benzodiazepines in patients prescribed methadone
because of the possible association with increased
overdose risk. However, in stable patients on long-
term low doses of a benzodiazepine plus methadone,
the panel found insufficient evidence for or against
routine discontinuation of the benzodiazepine,
though a careful consideration of potential risks rela-
tive to benefits is warranted.
Finally, care is needed when combining methadone
with other drugs that may prolong QTc intervals. In
spontaneously reported cases of methadone-
associated arrhythmia, antiretroviral drugs for human
immunodeficiency virus were the most common coad-
ministered drugs.51 The ECG should be carefully moni-
tored and doses of methadone and/or other drugs
adjusted to keep the QTc within a safe range, as dis-
cussed elsewhere in this Guideline.
The panel recommends that clinicians review
patient medications prior to initiation of methadone
and consider discontinuation or dose reduction of
medications with potential interactions or additive
side effects (Table 1). If methadone is initiated, the
panel recommends close monitoring following meth-
adone initiation. In patients on methadone, clini-
cians should review new medications for potential
interactions before starting them, monitor for inter-
actions if they are used, and make appropriate meth-
adone dose changes when a CYP inducer or inhibitor
is discontinued or when the dose is adjusted. For
example, discontinuation of a CYP inducer in a pa-
tient prescribed methadone could result in high
methadone levels, potentially increasing the risk for
overdose.
Methadone Use in Pregnancy
 The panel recommends monitoring of neonates
born to mothers receiving methadone for neonatal
abstinence syndrome and treatment for neonatal
abstinence syndrome when present (strong recom-
mendation, moderate-quality evidence).
Neonatal abstinence syndrome occurs in three-
quarters or more of infants exposed to methadone
prenatally.20,43,49,50,64,75,81,82,86,87,110 Evidence on
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comparative risk of neonatal abstinence syndrome
associated with different opioids is limited but may be
higher with methadone than buprenorphine.33,46
Although most studies have evaluated the incidence of
neonatal abstinence syndrome following maternal use
of methadone for treatment of opioid addiction,
methadone has also become frequently used for
treatmentof chronicpain inwomenof childbearingage.
Opioid agonist treatment withmethadone is the cur-
rent standard of care for opioid addiction during preg-
nancy in order to improve both maternal and fetal
outcomes.19 Detailed guidance regarding manage-
ment of addiction during pregnancy is beyond the
scope of this Guideline but is available from the Amer-
ican Congress of Obstetrics and Gynecology.19 For
women with chronic pain, clinicians should weigh the
benefits and harms of methadone and other opioids
when considering its use during pregnancy and inform
women of the potential risks to the newborn, as well as
the risk of opioid withdrawal with discontinuation of
methadone during pregnancy. The panel recommends
monitoring of all newborns born to mothers receiving
methadone for neonatal abstinence syndrome and
provision of appropriate treatments when it occurs.
Conclusions
Use of methadone for treatment of chronic pain has
increased dramatically, in part because of its lower cost
relative to other long-acting opioids, despite limited ev-
idence of efficacy for treatment of chronic pain.15 Meth-
adone maintenance therapy is a mainstay of treatment
for opioid addiction and is associated with reduced her-
oin and illicit drug use, greater retention in therapy, and
a trend toward reduced mortality risk.71 At the same
time, overdoses associated with methadone use have
increased dramatically, methadone is associated with
unique pharmacologic properties that complicate its
use, and alternatives to methadone are available for
treatment of both chronic pain and opioid addiction. Af-
ter a review of the available evidence, an expert panel
convened by APS, CPDD, and HRS concludes that mea-
sures can be taken to promote safer use of methadone.
The recommendations presented in this Guideline are
based on the underlying assumption that safe use of
methadone requires clinical skills and knowledge in
assessing and balancing potential risks against potential
benefits of methadone, monitoring andmanagement of
risks, with the core goal of promoting patient safety and
preventing avoidable harms, including serious events
such as accidental overdose and fatal arrhythmia. Unlike
other Guidelines,60,70,92 which primarily focused on
prevention of arrhythmia, the recommendations in this
Guideline also address aspects of patient risk
assessment, education and counseling, dose initiation
and titration, monitoring, and medication interactions
that are directly or indirectly related to risk of
respiratory depression, thought to be the primary cause
of methadone-associated deaths.
Although these guidelines are based on a systematic
review of the evidence on methadone safety, the panel
identified numerous research gaps. In fact, the panel
only rated 4 recommendations as supported by even
moderate-quality evidence. Nonetheless, the panel
came to near-unanimous consensus on almost all of its
recommendations, including the need to educate and
counsel patients on methadone safety, use of ECG to
identify persons at greater risk for methadone-
associated arrhythmia, use of alternative opioids in pa-
tients at high risk of complications related toQTc interval
prolongation, careful dose initiation and titration of
methadone, and diligent monitoring and follow-up.
The panel acknowledges that implementation of these
guidelines has important implications for resource utiliza-
tionandcost.However, at this time there is insufficient ev-
idence to reliably estimate or model the costs associated
with implementation. Given the number of potentially
preventable deaths associated with methadone and the
availability of alternative treatments, the panel
concludedthatenhancedefforts tomitigate risksofmeth-
adone are justified despite the limited evidence with
which to estimate their potential impact. Research is ur-
gently needed to confirm the effectiveness and cost-
effectiveness of the recommendations in this Guideline.
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